MRNS

Marinus Pharmaceuticals Inc

A biopharmaceutical company in Pennsylvania that develops treatments for rare seizure disorders. Its flagship product, ZTALMY (ganaxolone), approved in 2022, is the first FDA-approved therapy for seizures tied to CDKL5 deficiency disorder, a rare genetic condition. Founded in 2003, the company's name comes from the Latin word for "of the sea," a nod to its mission of calm waters for patients.

No Schedule 13D or 13G filings recorded.